Buy Rating on Olema Pharmaceuticals Amidst Promising Oncology Developments and Competitive Edge

TipRanksApr 12 23:55

FATE, ALPN and RLAY Are Among After Hour Movers

Seeking AlphaApr 11 05:20

Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference

SAN FRANCISCO, April 08, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema", "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and

GlobeNewswireApr 9 04:30

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, April 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, develo

GlobeNewswireApr 3 04:29

Goldman Sachs Initiates Coverage On Olema Pharmaceuticals With Buy Rating, Announces Price Target of $24

Goldman Sachs analyst Richard Law initiates coverage on Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy rating and announces Price Target of $24.

BenzingaApr 2 19:09

Olema Pharmaceuticals(OLMA.US) Director Sells US$219.4K in Common Stock

$Olema Pharmaceuticals(OLMA.US)$ Director Harmon Cyrus sold 20,000 shares of Common Stock on Mar 28, 2024 at an average price of $10.97 for a total value of $219.4K.Source: Announcement What is statem

Futu NewsMar 30 05:41